Company: AIP
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001667011-25-000022
Chunk: 240

Company: Arteris, Inc.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part II, Item 5
Chunk 240
---
Table of Contents

Item 5. Other Information

10b5-1 plans:

On March 5, 2025, Charles Janac, Chief Executive Officer (CEO), adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 186,757 shares of the Company’s common stock until June 30, 2026.

On March 5, 2025, Charles Janac, CEO, as the manager of Bayview Legacy, LLC, adopted a Rule 10b5-1 trading arrangement of Bayview Legacy LLC that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 840,000 shares of the Company’s common stock until June 30, 2026.

On March 6, 2025, Paul Alpern, Vice President and General Counsel, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 115,533 shares of the Company’s common stock until August 31, 2026.

On March 7, 2025, Raman Chitkara, Director, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 15,000 shares of the Company’s common stock until June 30, 2026.

On March 12, 2025, Laurent Moll, Chief Operating Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 204,974 shares of the Company’s common stock until June 30, 2026.

70